Form D · Biotechnology
PanTheryx, Inc.
Boulder, CO · CIK 0001416162
Offering snapshot reported Oct 11, 2023 · SEC filing
- Reported sold
- $52.3M Offering amount: $60M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 2, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 11, 2023 | Initial | $52,289,052 | No comparison | 1 | SEC filing |
| Apr 28, 2021 | Initial | $9,437,369 | No comparison | 37 | SEC filing |
| Jul 13, 2018 | Initial | $10,711,756 | No comparison | 5 | SEC filing |
| Sep 27, 2017 | Initial | $8,861,523 | No comparison | 1 | SEC filing |
| Apr 28, 2015 | Amendment | $9,260,818 | $1,937,490vs Jan 21, 2015 | 37 | SEC filing |
| Jan 21, 2015 | Amendment | $7,323,328 | $2,295,455vs May 21, 2014 | 35 | SEC filing |
| May 21, 2014 | Amendment | $5,027,873 | $0vs Apr 17, 2014 | 27 | SEC filing |
| Apr 17, 2014 | Amendment | $5,027,873 | $600,000vs Apr 9, 2014 | 25 | SEC filing |
| Apr 9, 2014 | Amendment | $4,427,873 | $77,000vs Mar 25, 2014 | 25 | SEC filing |
| Mar 25, 2014 | Amendment | $4,350,873 | $2,911,015vs May 3, 2013 | 23 | SEC filing |
| May 3, 2013 | Initial | $1,439,858 | No comparison | 10 | SEC filing |
| Aug 20, 2012 | Amendment | $3,541,100 | $1,975,000vs Apr 24, 2012 | 26 | SEC filing |
| Apr 24, 2012 | Initial | $1,566,100 | No comparison | 14 | SEC filing |
| Dec 8, 2011 | Amendment | $1,625,805 | $825,800vs Jun 23, 2011 | 15 | SEC filing |
| Jun 23, 2011 | Amendment | $800,005 | $620,005vs Jan 10, 2011 | 5 | SEC filing |
| Mar 18, 2011 | Amendment | $450,000 | $270,000vs Jan 10, 2011 | 3 | SEC filing |
| Jan 10, 2011 | Initial | $180,000 | No comparison | 3 | SEC filing |
| Oct 22, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-494308
Deemed purchase price; consideration was non-monetary
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| n/a | None |
Source: Form D, filed Oct 11, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Abramson | Director |
| Mark A. Braman | Director, Executive |
| Craig Cogut | Director |
| David Cogut | Director |
| David J. Cook | Director |
| Peter Erickson | Director |
| Thomas Feeley | Executive |
| N Stuart Harris | Director |
| James T. Hau | Executive |
| Scott A. Hyman | Executive |
| Holger Liepmann | Director |
| Chris Lindsay | Executive |
| Mehmet Oz | Director |
| Wes Parris | Director, Executive |
| Thomas Schultz | Executive |
| Rajiv Shah | Director |
| George Stagnitti | Executive |
| Tim Starzl | Director, Executive, Promoter |
| Timothy Starzl | Director, Executive |
| Bimla Starzl | Executive |
| Gary Wes Thomas | Executive |
| Feeley Tom | Executive |
| Peter J. Vitulli | Director |
| Thomas Washing | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4845 Pearl East Circle Suite 101
Boulder, CO, 80301
Boulder, CO, 80301